BTG2019 HOME
Dear Colleagues and Friends,
As the conference chairs of the 9th International Hematologic Malignancies Conference: Bridging the Gap 2019 (BTG2019), scheduled for MAR 15- 17, 2019 in FUZOU, CHINA, it is our pleasure to invite you to participate in this unique and premier event. Here you will have an opportunity to align with the premier conference dedicated to hematology/oncology specialists from around the globe. (Conference website: www.aphcon.org/btg2019).
Conference Venue: Shangri-La Hotel, Fuzou
9 Xinquan S Rd, NanMen ShangQuan, Gulou Qu, Fuzhou Shi, Fujian Sheng, China, 350001
Tel: +86 591 8798 8888
Homepage: www.shangri-la.com/fuzhou/shangrila/
BTG2019 is one of the largest and most important conferences to be held in the Asia Pacific region concerned with the research and treatment of hematologic malignancies. More than 500 hematologic malignancy experts are expected to attend the three-day conference.
There are many opportunities for industry to support the conference’s educational programs, annual meeting materials and services, such as tradeshow exhibition, satellite symposium participation, exclusive supporter options and others. Each opportunity promises to provide a significant presence for companies during the conference.
We thank you for your support and considerations.
Sincerely,
As the conference chairs of the 9th International Hematologic Malignancies Conference: Bridging the Gap 2019 (BTG2019), scheduled for MAR 15- 17, 2019 in FUZOU, CHINA, it is our pleasure to invite you to participate in this unique and premier event. Here you will have an opportunity to align with the premier conference dedicated to hematology/oncology specialists from around the globe. (Conference website: www.aphcon.org/btg2019).
Conference Venue: Shangri-La Hotel, Fuzou
9 Xinquan S Rd, NanMen ShangQuan, Gulou Qu, Fuzhou Shi, Fujian Sheng, China, 350001
Tel: +86 591 8798 8888
Homepage: www.shangri-la.com/fuzhou/shangrila/
BTG2019 is one of the largest and most important conferences to be held in the Asia Pacific region concerned with the research and treatment of hematologic malignancies. More than 500 hematologic malignancy experts are expected to attend the three-day conference.
There are many opportunities for industry to support the conference’s educational programs, annual meeting materials and services, such as tradeshow exhibition, satellite symposium participation, exclusive supporter options and others. Each opportunity promises to provide a significant presence for companies during the conference.
We thank you for your support and considerations.
Sincerely,
Surapol Issaragrisil, MD
|
Xiao Jun Huang, MD, PhD
|
Hari Parmeswaran, MD
|
Jianda Hu, MD
|